Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Return on Equity (2018 - 2025)

UroGen Pharma's Return on Equity history spans 8 years, with the latest figure at 1.39% for Q4 2025.

  • For Q4 2025, Return on Equity rose 1657.0% year-over-year to 1.39%; the TTM value through Dec 2025 reached 1.39%, up 1657.0%, while the annual FY2025 figure was 2.69%, 74.0% down from the prior year.
  • Return on Equity reached 1.39% in Q4 2025 per URGN's latest filing, down from 1.58% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 26.16% in Q1 2022 to a low of 15.18% in Q4 2024.
  • Average Return on Equity over 5 years is 2.17%, with a median of 1.41% recorded in 2025.
  • Peak YoY movement for Return on Equity: surged 2751bps in 2022, then plummeted -2507bps in 2023.
  • A 5-year view of Return on Equity shows it stood at 5.55% in 2021, then skyrocketed by 126bps to 1.44% in 2022, then soared by 33bps to 1.91% in 2023, then plummeted by -896bps to 15.18% in 2024, then surged by 109bps to 1.39% in 2025.
  • Per Business Quant, the three most recent readings for URGN's Return on Equity are 1.39% (Q4 2025), 1.58% (Q3 2025), and 2.22% (Q2 2025).